Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44904 | 1.00 | HDAC8 (0.58) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29350881 | 1.00 | HDAC8 (0.58) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1613174 | 1.00 | HDAC8 (0.58) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5965416 | 0.89 | HDAC8 (0.52) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21690291 | 0.86 | CYP2C9 (0.51) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29398382 | 0.86 | CYP2C9 (0.51) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29398451 | 0.86 | CYP2C9 (0.51) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL12958085 | 0.86 | HDAC8 (0.58) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29868418 | 0.86 | HDAC8 (0.58) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15745971 | 0.85 | HDAC8 (0.57) | HDAC8HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023042201-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | WO | claimed |
| EP-3387004-B1 | CYCLIC PEPTIDES TARGETING ALPHA4 BETA7 INTEGRIN | ZEALAND PHARMA AS (DK) | 2021-10-06 | — | — | EP | claimed |
| EP-3464324-B1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING BV (NL) | 2021-04-07 | — | — | EP | claimed |
| CN-105143245-B | Anti-scaling material | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20200102348-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2020-04-02 | — | — | US | claimed |
| EP-2951195-B1 | ANTIFOULING MATERIALS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2020-02-19 | — | — | EP | claimed |
| WO-2019179985-A1 | INHIBITORS OF MINT AND USES THEREOF | UNIVERSITY OF COPENHAGEN (DK) | 2019-09-26 | — | — | WO | claimed |
| US-10344054-B2 | Angiotensin-1-receptor antagonists | FERRING B.V. (NL) | 2019-07-09 | — | — | US | claimed |
| EP-3464324-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | Ferring B.V. (NL) | 2019-04-10 | — | — | EP | claimed |
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | FERRING B.V. (NL) | 2017-12-07 | — | — | US | claimed |
| EP-0980253-B1 | SOMATOSTATIN AND SOMATOSTATIN AGONISTS FOR TREATING INSULIN INSENSITIVITY AND SYNDROME X | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-31 | — | — | EP | claimed |
| EP-1355940-A2 | UROTENSIN-II AGONISTS AND ANTAGONISTS | The Administrators of The Tulane Educational Fund (US) | 2003-10-29 | — | — | EP | claimed |
| EP-0981363-B1 | SOMATOSTATIN AGONISTS FOR DECREASING BODY WEIGHT | SOD CONSEILS RECH APPLIC (FR) | 2003-07-30 | — | — | EP | claimed |
| EP-0829011-B1 | INHIBITION OF AMYLIN RELEASE | UNIV BUCKINGHAM (GB) | 2002-08-28 | — | — | EP | claimed |
| WO-2002032932-A2 | UROTENSIN-II AGONISTS AND ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2002-04-25 | — | — | WO | claimed |
| EP-0859785-B1 | CYCLIC PEPTIDE ANALOGS OF SOMATOSTATIN | BIOMEASURE INC (US) | 2001-05-30 | — | — | EP | claimed |
| EP-0644893-B1 | INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH | BIOMEASURE INC (US) | 2000-04-19 | — | — | EP | claimed |
| US-5968903-A | HELICOBACTER AND ANTIGROWTH AGENTS, USING SOMATOSTATIN OR AGONIST | BIOMEASURE, INCORPORATED (US) | 1999-10-19 | — | — | US | claimed |
| EP-0542934-B1 | USE OF SOMATOSTATIN ANALOGUES FOR TREATING MELANOMAS | BIOMEASURE INC (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0395417-B1 | Linear somatostatin analogues | UNIV TULANE (US) | 1995-02-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | AGTR1, AGTR2, REN | HDAC8 574/4885HDAC3 2542/4885HDAC1 1351/4885 |
| US-20200102348-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | HDAC8 574/4885HDAC3 2542/4885HDAC1 1351/4885 |
| US-10344054-B2 | Angiotensin-1-receptor antagonists | AGTR1, AGTR2, AGT | HDAC8 926/4885HDAC3 3311/4885HDAC1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.